OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
May 10, 2021
The collaboration, which has been in place since 1998, will focus on drug discovery, translational medicine research, and pharmaceutical development.
May 07, 2021
Eli Lilly and Company has partnered with leading diabetes tech firms to offer app compatibility with insulin smart pens to streamline diabetes management with automated data collection.
Vectura and Inspira Pharmaceuticals have joined forces to develop a potential inhaled therapy for COVID-19.
May 03, 2021
This new collaboration between Vyant Bio, Ordaōs Bio, and Cellaria mitigates risk in the drug discovery process using artificial intelligence and in-vitro “avatar” clinical trials.
AMRI will increase R&D and manufacturing capabilities for orphan and rare disease products.
Both the European Commission and FDA have granted approval to GlaxoSmithKline’s Jemperli (dostarlimab) for treating endometrial cancer.
Applying a QbD approach helps address excipient variability and other quality features.
Vaccine development is inherently challenging; however, in light of the COVID-19 pandemic, innovations have been prioritized, leading to accelerated development processes.
Aprecia and Glatt investigate manufacturing technologies to widen the formulation design space for oral delivery.
May 02, 2021
Mass spectrometry and automation are growing in importance for protein characterization, but further improvements are still needed.